Symbols / TMCI Stock $1.98 +8.79% Treace Medical Concepts, Inc.

Healthcare • Medical Devices • United States • NMS
TMCI (Stock) Chart
O: — H: — L: — C: — V: —
SMA 20: — SMA 50: — SMA 200: —
Stock Fundamentals
Scroll to Statements
Index EQUITY
Sector Healthcare
Industry Medical Devices
CEO Mr. John T. Treace
Exch · Country NMS · United States
Market Cap 128.27M
Enterprise Value 151.06M
Income -59.00M
Sales 212.69M
FCF (ttm) -10.09M
Book/sh 1.37
Cash/sh 0.75
Employees 450
Insider 10d —
IPO Apr 23, 2021
Div forward ($/yr)
Div TTM ($/yr)
Dividend Yield
Ex-Div Date
5Y Avg Yield
Yield vs 5Y Avg
Payout 0.00%
P/E —
Forward P/E -2.20
PEG —
P/S 0.60
P/B 1.45
P/C —
EV/EBITDA -3.39
EV/Sales 0.71
Quick Ratio 2.96
Current Ratio 4.31
Debt/Eq 82.29
LT Debt/Eq —
EPS (ttm) -0.93
EPS next Y -0.90
EPS Growth —
Revenue Growth -9.00%
EPS Gr Q/Q —
Rev Gr Q/Q —
Earnings (next) 2026-05-08
Earnings (prior) 2026-02-27
ROA -16.61%
ROE -58.94%
ROIC —
Gross Margin 79.81%
Oper. Margin -9.47%
Profit Margin -27.74%
Shs Outstand 64.78M
Shs Float 47.93M
Insider Own 24.77%
Instit Own 56.35%
Short Float 9.35%
Short Ratio 4.85
Short Interest 4.83M
52W High 7.78
vs 52W High -74.55%
52W Low 1.17
vs 52W Low 69.23%
Beta 0.88
Impl. Vol. 1.05%
Rel Volume 0.38
Avg Volume 877.79K
Volume 334.33K
Target (mean) $4.25
Tgt Median $4.00
Tgt Low $2.00
Tgt High $7.00
# Analysts 4
Recom Hold
Prev Close $1.82
Price $1.98
Change 8.79%
About

Treace Medical Concepts, Inc., a medical technology company, designs, manufactures, and markets medical devices in the United States. The company offers Lapiplasty System, enables surgeons to correct all three dimensions of the bunion deformity, stabilize the first TMT joint, and allow return to weight-bearing in a walking boot; minimally invasive products for four bunion classes; Nanoplasty 3D Minimally Invasive Bunion Correction System delivers a reproducible 3D correction of the bunion deformity through a cosmetically appealing; and Percuplasty Percutaneous 3D Bunion Correction System that provides 3D correction of the bunion deformity through percutaneous incisions. It also provides Adductoplasty System, a system designed for the correction of metatarsus adductus deformities and osteoarthritis of the midfoot; SpeedMTP Rapid Compression Implant; SpeedPlate Implant Fixation Platform to address the fusion of larger bones of the midfoot and rearfoot; SpeedPlate Micro-Quad implant, an implant designed for stability and fit in small incision surgical approaches; and SpeedAkin Anatomic Compression Implant. In addition, the company offers The IntelliGuide patient specific instrumentation provides patient-specific, 3D-printed cut guides, and a pre-operative plan for a complete picture of the deformity and correction. Further, it provides FastGrafter Autografter Harvesting System; SpeedRelease Guided Release Instrument; TriTome Triple-Edge Release Instrument; RazorTome 7mm Precision Osteotome; LapiTome Hooked Bone Removal Osteotome; GreatRelease Rapid MTP Release Instrument; CornerChisel Release Tool; NanoRasp MIS Bone Contouring Tool; FeatherRasp Rapid Bone Contouring Instrument; and Akinator Single-cut Akin Wedge Osteotomy tool. Additionally, the company offers biologics and wedges, such as Treace Allograft Wedges; and CortiFuse Flowable Cortical Fibers. Treace Medical Concepts, Inc. was founded in 2013 and is headquartered in Ponte Vedra, Florida.

Valuation Models

Price estimates from analyst targets and simple models.

1. Analyst consensus
$4.25
Mean price target
2. Current target
$1.98
Latest analyst target
3. DCF / Fair value
$-2.80
Simplified: (Free Cash Flow ÷ Shares) × 18 (P/FCF multiple). Not a …
Ratings
Current target
$1.98
Low
$2.00
High
$7.00
Mean
$4.25

Latest analyst rating changes

Date Action Analyst Rating Change Price Target
2026-03-02 main Lake Street Buy → Buy $7
2026-01-07 main Stifel Hold → Hold $3
2025-12-18 main Truist Securities Hold → Hold $3
2025-11-10 reit Truist Securities Hold → Hold $4
2025-11-07 main UBS Neutral → Neutral $6
2025-11-07 down JP Morgan Neutral → Underweight $5
2025-11-07 down BTIG Buy → Neutral —
2025-10-15 main Truist Securities Hold → Hold $7
2025-09-04 main Truist Securities Hold → Hold $8
2025-08-08 main UBS Neutral → Neutral $7
2025-08-08 main Stifel Hold → Hold $6
2025-05-09 main UBS Neutral → Neutral $9
2025-04-11 main Truist Securities Hold → Hold $8
2025-03-13 main Truist Securities Hold → Hold $10
2025-03-03 main Truist Securities Hold → Hold $10
2024-12-31 init Lake Street — → Buy $15
2024-12-18 main Truist Securities Hold → Hold $8
2024-11-06 main Stifel Hold → Hold $8
2024-10-14 main Truist Securities Hold → Hold $6
2024-08-07 main UBS Neutral → Neutral $7
News
RSS: Latest TMCI news
Insider Transactions
Filed Date Insider Relationship Transaction Shares Price Value SEC
2026-04-01 HAIR MARK Chief Financial Officer — 100,000 $0.00 $0
2026-02-10 SCANLAN SEAN F Officer — 16,875 $1.05 $17,719
2026-01-22 GUGLIELMINO GAETANO M Officer — 150,000 $0.00 $0
2026-01-22 HAIR MARK Chief Financial Officer — 375,000 $0.00 $0
2026-01-22 SCANLAN SEAN F Chief Technology Officer — 262,500 $0.00 $0
2026-01-22 TREACE JOHN T. Chief Executive Officer — 250,000 $0.00 $0
2026-01-22 ELDER SCOT MICHAEL Officer — 262,500 $0.00 $0
2026-01-21 SCANLAN SEAN F Chief Technology Officer — 53,500 $0.72 $38,520
2025-07-18 SCANLAN SEAN F Officer — 33,437 $0.72 $24,001
2025-05-20 HAMILTON LAWRENCE W Director — 23,917 $0.00 $0
Financials
Statement View
Amounts in millions (2 decimals, no suffix) • EPS per share (2 decimals) • Trend = period evolution • YoY Growth = previous period %
Line Item Trend 2025-12-31 2024-12-31 2023-12-31 2022-12-31
Total Revenue
212.69
+1.59%
209.36
+11.89%
187.12
+31.92%
141.84
Operating Revenue
212.69
+1.59%
209.36
+11.89%
187.12
+31.92%
141.84
Cost Of Revenue
42.94
+4.49%
41.09
+16.80%
35.18
+37.79%
25.53
Reconciled Cost Of Revenue
42.94
+4.49%
41.09
+16.80%
35.18
+37.79%
25.53
Gross Profit
169.75
+0.88%
168.26
+10.75%
151.94
+30.64%
116.31
Operating Expense
223.91
-0.02%
223.95
+10.12%
203.37
+34.55%
151.15
Research And Development
20.28
-1.49%
20.59
+33.35%
15.44
+13.66%
13.58
Selling General And Administration
203.62
+0.13%
203.36
+8.21%
187.93
+36.61%
137.57
Selling And Marketing Expense
140.88
-4.58%
147.64
+4.79%
140.89
+34.74%
104.57
General And Administrative Expense
62.74
+12.61%
55.72
+18.48%
47.03
+42.52%
33.00
Other Gand A
62.74
+12.61%
55.72
+18.48%
47.03
+42.52%
33.00
Total Expenses
266.84
+0.68%
265.05
+11.11%
238.55
+35.01%
176.68
Operating Income
-54.15
+2.75%
-55.69
-8.28%
-51.43
-47.59%
-34.84
Total Operating Income As Reported
-54.15
+2.75%
-55.69
-8.28%
-51.43
-47.59%
-34.84
EBITDA
-43.06
-2.36%
-42.07
-7.84%
-39.01
-7.51%
-36.28
Normalized EBITDA
-40.32
+4.15%
-42.07
-7.84%
-39.01
-22.66%
-31.80
Reconciled Depreciation
10.62
+26.18%
8.42
+57.31%
5.35
+150.91%
2.13
EBIT
-53.68
-6.33%
-50.49
-13.81%
-44.36
-15.47%
-38.42
Total Unusual Items
-2.74
0.00
0.00
+100.00%
-4.48
Total Unusual Items Excluding Goodwill
-2.74
0.00
0.00
+100.00%
-4.48
Special Income Charges
-2.74
0.00
0.00
+100.00%
-4.48
Other Special Charges
2.74
—
—
4.48
Net Income
-59.00
-5.85%
-55.74
-12.55%
-49.53
-15.68%
-42.81
Pretax Income
-59.00
-5.85%
-55.74
-12.55%
-49.53
-15.68%
-42.81
Net Non Operating Interest Income Expense
-2.54
-570.98%
-0.38
-124.31%
1.56
+150.53%
-3.08
Interest Expense Non Operating
5.32
+1.22%
5.26
+1.72%
5.17
+17.49%
4.40
Net Interest Income
-2.54
-570.98%
-0.38
-124.31%
1.56
+150.53%
-3.08
Interest Expense
5.32
+1.22%
5.26
+1.72%
5.17
+17.49%
4.40
Interest Income Non Operating
2.78
-43.06%
4.88
-27.49%
6.73
+412.26%
1.31
Interest Income
2.78
-43.06%
4.88
-27.49%
6.73
+412.26%
1.31
Other Income Expense
-2.31
-811.42%
0.32
-5.26%
0.34
+107.00%
-4.89
Other Non Operating Income Expenses
0.43
+33.33%
0.32
-5.26%
0.34
+184.86%
-0.40
Tax Rate For Calcs
0.00
0.00
0.00
0.00
Tax Effect Of Unusual Items
0.00
0.00
0.00
0.00
Net Income Including Noncontrolling Interests
-59.00
-5.85%
-55.74
-12.55%
-49.53
-15.68%
-42.81
Net Income From Continuing Operation Net Minority Interest
-59.00
-5.85%
-55.74
-12.55%
-49.53
-15.68%
-42.81
Net Income From Continuing And Discontinued Operation
-59.00
-5.85%
-55.74
-12.55%
-49.53
-15.68%
-42.81
Net Income Continuous Operations
-59.00
-5.85%
-55.74
-12.55%
-49.53
-15.68%
-42.81
Normalized Income
-56.27
-0.94%
-55.74
-12.55%
-49.53
-29.21%
-38.33
Net Income Common Stockholders
-59.00
-5.85%
-55.74
-12.55%
-49.53
-15.68%
-42.81
Diluted EPS
—
-0.90
-11.11%
-0.81
-5.19%
-0.77
Basic EPS
—
-0.90
-11.11%
-0.81
-5.19%
-0.77
Basic Average Shares
—
62.11
+2.07%
60.85
+10.09%
55.28
Diluted Average Shares
—
62.11
+2.07%
60.85
+10.09%
55.28
Diluted NI Availto Com Stockholders
-59.00
-5.85%
-55.74
-12.55%
-49.53
-15.68%
-42.81
Preferred Stock Dividends
—
—
—
—
Line Item Trend 2025-12-31 2024-12-31 2023-12-31
Total Assets
190.58
-12.21%
217.09
-13.82%
251.91
Current Assets
132.05
-18.18%
161.40
-18.63%
198.36
Cash Cash Equivalents And Short Term Investments
48.37
-36.09%
75.68
-38.57%
123.20
Cash And Cash Equivalents
10.71
-5.66%
11.35
-12.57%
12.98
Cash Equivalents
7.84
+30.71%
6.00
+89.72%
3.16
Cash Financial
2.87
-46.37%
5.36
-45.48%
9.82
Other Short Term Investments
37.66
-41.46%
64.33
-41.64%
110.22
Receivables
42.16
+3.31%
40.80
+7.20%
38.06
Accounts Receivable
42.16
+3.31%
40.80
+7.20%
38.06
Gross Accounts Receivable
43.98
+4.39%
42.13
+7.90%
39.04
Allowance For Doubtful Accounts Receivable
-1.82
-37.56%
-1.33
-35.31%
-0.98
Inventory
36.03
-8.21%
39.26
+34.23%
29.25
Prepaid Assets
—
—
—
Other Current Assets
5.50
-2.93%
5.67
-27.84%
7.85
Total Non Current Assets
58.53
+5.09%
55.69
+4.00%
53.55
Net PPE
37.37
+8.64%
34.40
+8.98%
31.56
Gross PPE
61.23
+23.21%
49.70
+23.29%
40.31
Accumulated Depreciation
-23.87
-55.96%
-15.30
-74.95%
-8.75
Properties
0.00
0.00
0.00
Machinery Furniture Equipment
8.81
+13.98%
7.73
+23.67%
6.25
Construction In Progress
1.07
+74.67%
0.61
-45.11%
1.11
Other Properties
40.76
+31.02%
31.11
+32.29%
23.52
Leases
10.59
+3.39%
10.24
+8.69%
9.43
Goodwill And Other Intangible Assets
19.94
-4.55%
20.89
-4.35%
21.84
Goodwill
12.81
+0.00%
12.81
+0.00%
12.81
Other Intangible Assets
7.12
-11.76%
8.07
-10.53%
9.03
Other Non Current Assets
1.22
+200.00%
0.41
+178.77%
0.15
Total Liabilities Net Minority Interest
103.25
-0.91%
104.20
-8.57%
113.97
Current Liabilities
30.64
-12.28%
34.92
-22.45%
45.03
Payables And Accrued Expenses
21.88
-14.93%
25.71
-13.45%
29.71
Payables
6.73
-36.08%
10.52
-11.09%
11.84
Accounts Payable
6.73
-36.08%
10.52
-11.09%
11.84
Current Accrued Expenses
15.15
-0.29%
15.19
-15.01%
17.88
Pensionand Other Post Retirement Benefit Plans Current
6.33
-27.23%
8.70
-20.10%
10.89
Current Debt And Capital Lease Obligation
2.30
+456.17%
0.41
-70.58%
1.40
Current Debt
1.75
—
—
Other Current Borrowings
1.75
—
—
Current Capital Lease Obligation
0.55
+33.66%
0.41
-70.58%
1.40
Other Current Liabilities
0.13
+36.08%
0.10
-96.80%
3.03
Total Non Current Liabilities Net Minority Interest
72.61
+4.82%
69.28
+0.49%
68.94
Long Term Debt And Capital Lease Obligation
69.56
+0.47%
69.24
+0.49%
68.90
Long Term Debt
55.58
+4.27%
53.31
+0.56%
53.01
Long Term Capital Lease Obligation
13.98
-12.25%
15.93
+0.27%
15.89
Other Non Current Liabilities
3.05
+8140.54%
0.04
+0.00%
0.04
Stockholders Equity
87.33
-22.64%
112.89
-18.16%
137.94
Common Stock Equity
87.33
-22.64%
112.89
-18.16%
137.94
Capital Stock
0.06
+3.23%
0.06
+0.00%
0.06
Common Stock
0.06
+3.23%
0.06
+0.00%
0.06
Preferred Stock
0.00
0.00
0.00
Share Issued
64.03
+2.64%
62.39
+1.03%
61.75
Ordinary Shares Number
63.86
+2.41%
62.36
+0.99%
61.75
Treasury Shares Number
0.17
+607.59%
0.02
+1820.44%
0.00
Additional Paid In Capital
337.37
+11.34%
303.00
+11.41%
271.97
Retained Earnings
-248.99
-31.06%
-189.99
-41.52%
-134.25
Gains Losses Not Affecting Retained Earnings
0.07
-25.77%
0.10
-40.49%
0.16
Treasury Stock
1.18
+321.00%
0.28
+2061.54%
0.01
Other Equity Adjustments
0.07
-25.77%
0.10
-40.49%
0.16
Total Equity Gross Minority Interest
87.33
-22.64%
112.89
-18.16%
137.94
Total Capitalization
142.91
-14.01%
166.20
-12.96%
190.95
Working Capital
101.42
-19.81%
126.48
-17.51%
153.33
Invested Capital
144.66
-12.96%
166.20
-12.96%
190.95
Total Debt
71.86
+3.17%
69.65
-0.92%
70.30
Net Debt
46.62
+11.12%
41.96
+4.82%
40.03
Capital Lease Obligations
14.53
-11.09%
16.35
-5.48%
17.30
Net Tangible Assets
67.39
-26.75%
92.00
-20.75%
116.10
Tangible Book Value
67.39
-26.75%
92.00
-20.75%
116.10
Derivative Product Liabilities
—
—
—
Interest Payable
0.24
-43.10%
0.42
+0.72%
0.42
Line Item Trend 2025-12-31 2024-12-31 2023-12-31 2022-12-31
Operating Cash Flow
-15.97
+57.03%
-37.17
-7.50%
-34.58
-12.81%
-30.65
Cash Flow From Continuing Operating Activities
-15.97
+57.03%
-37.17
-7.50%
-34.58
-12.81%
-30.65
Net Income From Continuing Operations
-59.00
-5.85%
-55.74
-12.55%
-49.53
-15.68%
-42.81
Depreciation Amortization Depletion
10.62
+26.18%
8.42
+57.31%
5.35
+150.91%
2.13
Depreciation And Amortization
10.62
+26.18%
8.42
+57.31%
5.35
+150.91%
2.13
Other Non Cash Items
3.72
+16.86%
3.19
+7.49%
2.96
+6.16%
2.79
Stock Based Compensation
33.82
+10.52%
30.60
+76.37%
17.35
+113.93%
8.11
Provisionand Write Offof Assets
0.83
-71.70%
2.95
+579.03%
0.43
+5.60%
0.41
Asset Impairment Charge
—
0.00
0.00
-100.00%
0.35
Operating Gains Losses
2.74
—
—
4.31
Gain Loss On Investment Securities
—
—
—
-0.17
Change In Working Capital
-8.58
+66.25%
-25.43
-161.04%
-9.74
-67.72%
-5.81
Change In Receivables
-2.09
+63.25%
-5.69
+38.86%
-9.30
+15.74%
-11.04
Changes In Account Receivables
-2.09
+63.25%
-5.69
+38.86%
-9.30
+15.74%
-11.04
Change In Inventory
3.22
+132.21%
-10.01
-1.65%
-9.85
-12.30%
-8.77
Change In Prepaid Assets
0.17
-92.41%
2.19
+280.66%
-1.21
-81.14%
-0.67
Change In Payables And Accrued Expense
-6.21
+32.63%
-9.22
-186.17%
10.70
-8.88%
11.74
Change In Accrued Expense
-2.41
+69.47%
-7.90
-204.98%
7.53
+5.66%
7.12
Change In Payable
-3.80
-189.11%
-1.31
-141.46%
3.17
-31.33%
4.61
Change In Account Payable
-3.80
-189.11%
-1.31
-141.46%
3.17
-31.33%
4.61
Change In Other Working Capital
0.04
-63.92%
0.10
+142.50%
0.04
—
Change In Other Current Assets
-0.50
-52.42%
-0.33
0.00
+100.00%
-0.15
Change In Other Current Liabilities
-3.21
-29.68%
-2.47
-1978.15%
-0.12
-103.87%
3.08
Investing Cash Flow
13.25
-62.54%
35.38
+143.51%
-81.30
-6.25%
-76.52
Cash Flow From Continuing Investing Activities
13.25
-62.54%
35.38
+143.51%
-81.30
-6.25%
-76.52
Net PPE Purchase And Sale
-13.52
-16.60%
-11.59
-1.18%
-11.46
+22.78%
-14.84
Purchase Of PPE
-13.52
-16.60%
-11.59
-1.18%
-11.46
+22.78%
-14.84
Capital Expenditure
-13.52
-16.60%
-11.59
-1.18%
-11.46
+22.78%
-14.84
Net Investment Purchase And Sale
26.77
-43.01%
46.97
+194.24%
-49.84
+19.19%
-61.68
Purchase Of Investment
-40.57
+43.32%
-71.58
+57.86%
-169.87
-167.89%
-63.41
Sale Of Investment
67.34
-43.20%
118.55
-1.23%
120.02
+6841.82%
1.73
Net Business Purchase And Sale
0.00
0.00
+100.00%
-20.00
0.00
Purchase Of Business
0.00
0.00
+100.00%
-20.00
0.00
Financing Cash Flow
2.08
+1198.13%
0.16
-99.85%
109.38
+425.73%
20.81
Cash Flow From Continuing Financing Activities
2.08
+1198.13%
0.16
-99.85%
109.38
+425.73%
20.81
Net Issuance Payments Of Debt
59.31
0.00
0.00
-100.00%
19.61
Issuance Of Debt
59.31
0.00
0.00
-100.00%
53.50
Repayment Of Debt
—
0.00
0.00
+100.00%
-33.89
Long Term Debt Issuance
59.31
0.00
0.00
-100.00%
53.50
Long Term Debt Payments
—
0.00
0.00
+100.00%
-33.89
Net Long Term Debt Issuance
59.31
0.00
0.00
-100.00%
19.61
Net Common Stock Issuance
0.00
0.00
-100.00%
107.53
0.00
Cash Dividends Paid
0.00
0.00
0.00
—
Proceeds From Stock Option Exercised
0.55
+27.57%
0.43
-77.10%
1.87
-14.54%
2.19
Net Other Financing Charges
-1.46
-446.27%
-0.27
-1961.54%
-0.01
+98.69%
-0.99
Changes In Cash
-0.64
+60.66%
-1.63
+74.86%
-6.49
+92.48%
-86.36
Beginning Cash Position
11.35
-12.57%
12.98
-33.33%
19.47
-81.60%
105.83
End Cash Position
10.71
-5.66%
11.35
-12.57%
12.98
-33.33%
19.47
Free Cash Flow
-29.49
+39.53%
-48.76
-5.92%
-46.03
-1.20%
-45.49
Interest Paid Supplemental Data
5.00
+0.85%
4.96
-4.10%
5.17
+17.49%
4.40
Amortization Of Securities
-0.12
+89.26%
-1.15
+18.56%
-1.41
-1015.87%
-0.13
Common Stock Issuance
0.00
0.00
-100.00%
107.53
0.00
Interest Paid CFF
-56.31
0.00
0.00
—
Issuance Of Capital Stock
0.00
0.00
-100.00%
107.53
0.00
SEC Filings

Recent 10-K, 10-Q, 8-K, and Form 4 (insider) filings.

Trades
Date User Broker Pattern Type Position Size Entry Price Trade P&L Status
Posts
Published Title Author Category